<?xml version="1.0" encoding="UTF-8"?>
<p>Neuraminidase inhibitorâ€“associated resistance mutations were detected in the NA gene of the postbaseline samples in 49 oseltamivir-treated children (2.3%), including 34 (1.6%) A/H1N1pdm09 viruses with the H274Y mutation and 15 (0.7%) A/H3N2 viruses with the R292K mutation (
 <xref rid="T3" ref-type="table">Table 3</xref>). No resistance mutations were detected in influenza B viruses. The emergence of resistance mutations was equally distributed over the entire 7 years of IRIS (
 <xref rid="T4" ref-type="table">Table 4</xref>). The prevalence of resistance was higher in children aged &lt;5 years (n = 39) compared with children aged &gt;5 years (n = 10; 
 <xref rid="T3" ref-type="table">Table 3</xref>). The children infected with viruses who acquired resistance mutations had a higher viral load at day 3 and/or day 6 compared with children infected with wild-type A/H1N1pdm09 and A/H3N2 virus (
 <xref ref-type="supplementary-material" rid="sup1">Supplementary Figures 7</xref> and 
 <xref ref-type="supplementary-material" rid="sup1">8</xref>). This difference was not observed at day 10, since most children had cleared the virus.
</p>
